Lantheus Alzheimer's Diagnostic Candidate Shows Promise in Trials

Dow Jones

Apr 30, 2025

By Rob Curran

Lantheus Holdings said an imaging agent designed to identify markers of Alzheimer's disease showed promise in two clinical trials.

The Bedford, Mass., maker of pharmaceuticals with radiological applications said its MK-6240 product candidate met primary end-points in clinical trials assessing its sensitivity and specificity. The company will use the data to support a New Drug Application to the Food and Drug Administration for the imaging agent in the third quarter.

The MK-6240 compound, used in Positron Emission Tomography, targets tau protein aggregation, associated with neurological diseases, including Alzheimer's disease.

"As a clinician, the ability to visualize tau pathology represents the opportunity for a seismic shift in how we diagnose and manage Alzheimer's disease," said Lantheus' medical director, Luca Passamonti.

Write to Rob Curran at rob.curran@wsj.com

(END) Dow Jones Newswires

April 30, 2025 09:02 ET (13:02 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531003718"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531003718\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531003718?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531003718","market":"nz","top_or_hot":-1,"title":"Lantheus Alzheimer's Diagnostic Candidate Shows Promise in Trials","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Lantheus Holdings said an imaging agent designed to identify markers of Alzheimer's disease showed promise in two clinical trials. \n</p>\n<p>\n  The Bedford, Mass., maker of pharmaceuticals with radiological applications said its MK-6240 product candidate met primary end-points in clinical trials assessing its sensitivity and specificity. The company will use the data to support a New Drug Application to the Food and Drug Administration for the imaging agent in the third quarter. \n</p>\n<p>\n  The MK-6240 compound, used in Positron Emission Tomography, targets tau protein aggregation, associated with neurological diseases, including Alzheimer's disease. \n</p>\n<p>\n  \"As a clinician, the ability to visualize tau pathology represents the opportunity for a seismic shift in how we diagnose and manage Alzheimer's disease,\" said Lantheus' medical director,  Luca Passamonti. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2025 09:02 ET (13:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lantheus Alzheimer's Diagnostic Candidate Shows Promise in Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLantheus Alzheimer's Diagnostic Candidate Shows Promise in Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-30 21:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Lantheus Holdings said an imaging agent designed to identify markers of Alzheimer's disease showed promise in two clinical trials. \n</p>\n<p>\n  The Bedford, Mass., maker of pharmaceuticals with radiological applications said its MK-6240 product candidate met primary end-points in clinical trials assessing its sensitivity and specificity. The company will use the data to support a New Drug Application to the Food and Drug Administration for the imaging agent in the third quarter. \n</p>\n<p>\n  The MK-6240 compound, used in Positron Emission Tomography, targets tau protein aggregation, associated with neurological diseases, including Alzheimer's disease. \n</p>\n<p>\n  \"As a clinician, the ability to visualize tau pathology represents the opportunity for a seismic shift in how we diagnose and manage Alzheimer's disease,\" said Lantheus' medical director,  Luca Passamonti. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 30, 2025 09:02 ET (13:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2531003718","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531003718","pubTimestamp":1746018120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Lantheus Holdings said an imaging agent designed to identify markers of Alzheimer's disease showed promise in two clinical trials.The Bedford, Mass., maker of pharmaceuticals with radiological applications said its MK-6240 product candidate met primary end-points in clinical trials assessing its sensitivity and specificity. The company will use the data to support a New Drug Application to the Food and Drug Administration for the imaging agent in the third quarter.The MK-6240 compound, used in Positron Emission Tomography, targets tau protein aggregation, associated with neurological diseases, including Alzheimer's disease.\"As a clinician, the ability to visualize tau pathology represents the opportunity for a seismic shift in how we diagnose and manage Alzheimer's disease,\" said Lantheus' medical director,  Luca Passamonti.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LNTH":"Lantheus Holdings, Inc.","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品"},"translate_title":"Lantheus阿尔茨海默病诊断候选药物在试验中显示出希望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LNTH":1},"content_text":"By Rob Curran \n\n\n \n\n\n  Lantheus Holdings said an imaging agent designed to identify markers of Alzheimer's disease showed promise in two clinical trials. \n\n\n  The Bedford, Mass., maker of pharmaceuticals with radiological applications said its MK-6240 product candidate met primary end-points in clinical trials assessing its sensitivity and specificity. The company will use the data to support a New Drug Application to the Food and Drug Administration for the imaging agent in the third quarter. \n\n\n  The MK-6240 compound, used in Positron Emission Tomography, targets tau protein aggregation, associated with neurological diseases, including Alzheimer's disease. \n\n\n  \"As a clinician, the ability to visualize tau pathology represents the opportunity for a seismic shift in how we diagnose and manage Alzheimer's disease,\" said Lantheus' medical director,  Luca Passamonti. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2025 09:02 ET (13:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}